19.94
1.82%
-0.37
Pre-market:
19.94
Artivion Inc stock is currently priced at $19.94, with a 24-hour trading volume of 144.90K.
It has seen a -1.82% decreased in the last 24 hours and a +0.96% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $20.24 pivot point. If it approaches the $19.65 support level, significant changes may occur.
Artivion Inc Stock (AORT) Financials Data
Artivion Inc (AORT) Revenue 2024
AORT reported a revenue (TTM) of $354.00 million for the quarter ending December 31, 2023, a +12.82% rise year-over-year.
Artivion Inc (AORT) Net Income 2024
AORT net income (TTM) was -$30.69 million for the quarter ending December 31, 2023, a -59.91% decrease year-over-year.
Artivion Inc (AORT) Cash Flow 2024
AORT recorded a free cash flow (TTM) of $11.39 million for the quarter ending December 31, 2023, a +180.42% increase year-over-year.
Artivion Inc (AORT) Earnings per Share 2024
AORT earnings per share (TTM) was -$0.75 for the quarter ending December 31, 2023, a -56.25% decline year-over-year.
Artivion Inc Stock (AORT) Latest News
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
Zacks Investment Research
Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?
Zacks Investment Research
Are Medical Stocks Lagging Artivion (AORT) This Year?
Zacks Investment Research
3 Buy-Rated Small Caps Flexing Big Growth
Zacks Investment Research
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
Zacks Investment Research
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
About Artivion Inc
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. Artivion Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
Cap:
|
Volume (24h):